kabutan

KISSEI PHARMA, Oct-Dec (3Q) Ordinary Profit Increases by 11%, Current Fiscal Year Dividend Revised Upward by 40 Yen

Fri Jan 30, 2026 3:30 pm JST Earnings

4547 KISSEI PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KISSEI PHARMACEUTICAL CO.,LTD. <4547> [TSE Prime] announced its financial results after the market closed on January 30th (15:30). The consolidated ordinary profit/loss for the cumulative third quarter of the fiscal year ending March 2026 (April to December) turned into a loss of 2.22 billion yen (compared to a profit of 5.29 billion yen in the same period last year).

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to drop 32.8% from the same period last year to 1.12 billion yen.

At the same time, the company has significantly increased its planned annual dividend for the current fiscal year from the original plan of 120 yen to 160 yen (compared to 100 yen in the previous period).

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit grew 10.9% from the same period last year, reaching 3.39 billion yen. The operating profit margin rose from 10.6% in the same period last year to 11.8%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 57,859 4,164 6,100 8,337 182.9 99.3 Jan 30, 2024 J-GAAP
Apr - Dec, 2024 65,669 4,238 5,298 8,840 201.4 76.0 Feb 3, 2025 J-GAAP
Apr - Dec, 2025 72,633 -3,682 -2,226 11,014 264.8 ー Jan 30, 2026 J-GAAP
YoY +10.6% － － +24.6% +31.5%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2025 Prev 49,669 4,237 4,522 4,916 118.6 60 Nov 4, 2025 J-GAAP
Oct - Mar, 2025 New 49,669 4,237 4,522 4,916 118.6 100 Jan 30, 2026 J-GAAP
Revision Rate 0.0% 0.0% 0.0% 0.0% 0.0%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 95,500 -2,600 -1,100 12,700 306.4 120 Nov 4, 2025 J-GAAP
Mar, 2026 New 95,500 -2,600 -1,100 12,700 306.4 160 Jan 30, 2026 J-GAAP
Revision Rate 0.0% 0.0% 0.0% 0.0% 0.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 45,864 3,992 4,737 6,712 153.9 55 May 7, 2025 J-GAAP
Oct - Mar, 2025 Guidance 49,669 4,237 4,522 4,916 118.6 100 Jan 30, 2026 J-GAAP
YoY +8.3% +6.1% -4.5% -26.8% -22.9%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,579 4,017 6,142 11,160 246.6 82 May 7, 2024 J-GAAP
Mar, 2025 88,330 5,773 6,974 11,961 274.2 100 May 7, 2025 J-GAAP
Mar, 2026 Guidance 95,500 -2,600 -1,100 12,700 306.4 160 Jan 30, 2026 J-GAAP
YoY +8.1% － － +6.2% +11.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 23,203 2,457 3,061 3,591 81.8 10.6 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 22,661 1,535 1,676 3,121 71.6 6.8 May 7, 2025 J-GAAP
Apr - Jun, 2025 22,191 2,108 2,915 4,519 107.9 9.5 Jul 29, 2025 J-GAAP
Jul - Sep, 2025 23,640 -8,945 -8,537 3,265 78.4 -37.8 Nov 4, 2025 J-GAAP
Oct - Dec, 2025 26,802 3,155 3,396 3,230 77.7 11.8 Jan 30, 2026 J-GAAP
YoY +15.5% +28.4% +10.9% -10.1% -5.1%

Related Articles